SCHEMBL30714672

SCHEMBL30714672

Cn1nc2ccc(OCc3ccccn3)cc2c1C(=O)NC1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
HPGDS O60760 1/20 0.42
P2RY12 Q9H244 1/20 0.41
BRD4 O60885 2/20 0.41
GRM4 Q14833 2/20 0.41
DRD4 P21917 1/20 0.41
GRM5 P41594 1/20 0.41
PRKDC P78527 2/20 0.41
HTR3A P46098 1/20 0.41
P2RX3 P56373 1/20 0.40
ITGA5 P08648 1/20 0.40
GABRA5 P31644 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
NR2F2 P24468 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK14 Q16539 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714550 0.90 KDM4E (0.46) DRD4HTR3AALDH1A1MAPK14SMO
SCHEMBL31539894 0.89 SMO (0.40) P2RY12BRD4GRM5PRKDCHTR3A
SCHEMBL26868541 0.86 ACSS2 (0.40) BRD4DRD4HTR3AMAPTMAPK14
SCHEMBL26696013 0.85 PDE5A (0.41) P2RY12BRD4DRD4GRM5HTR3A
SCHEMBL26868981 0.85 GRM4 (0.40) P2RY12BRD4GRM4GRM5PRKDC
SCHEMBL30714571 0.82 MMP3 (0.40) P2RY12BRD4GRM5PRKDCMAPK14
SCHEMBL30714715 0.82 HPGDS (0.41) RAB9ANPC1HPGDSHTR3AGABRA5
SCHEMBL26868378 0.82 GRM5 (0.42) RAB9ANPC1GRM5ALDH1A1MAPT
SCHEMBL30714638 0.81 P2RY12 (0.39) P2RY12BRD4GRM5PRKDCMAPK14
SCHEMBL26868537 0.81 DGAT2 (0.43) BRD4DRD4GRM5HTR3AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 RAB9A 2614/4885NPC1 349/4885HPGDS 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.